| 期刊論文| 1. | 陳姿婷、張文和(2003)。精神分裂症之多重用藥。生物精神醫學曁神經精神藥理學通訊，1，1-9。 延伸查詢 | | 2. | Tamminga, C. A.(2002)。Partial dopamine agonists in the treatment of psychosis。J Neural Transm，109，411-420。  | | 3. | Stahl, S. M.(2001)。Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors。J Clin Psychiatiy，62，841-842。 | | 4. | Stahl, S. M.(2001)。Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2, illustrating their mechanism of action。J Clin Psychiatiy，62，923-924。 | | 5. | Grunder, G.、Carlsson, A.、Wong, D. F.(2003)。Mechanism of new antipsychotic medications: occupancy is not just antagonism。Arch Gen Psychiatry，60，974-977。 | | 6. | Lieberman, J. A.(2004)。Dopamine partial agonists: a new class of antipsychotic。CNS Drugs，18，251-267。 | | 7. | Sartorius, N.、Fleischhacker, W. W.、Gjerris, A.(2002)。The usefulness and use of second-generation anti-psychotic medications。Curr Opin Psychiatry，15(suppl 1)，S1-S52。 | | 8. | Sartorius, N.、Fleischhacker, W. W.、Gjerris, A.(2003)。The usefulness and use of second-generation anti-psychotic medications--an update。Curr Opin Psychiatry，16(suppl 1)，S1-S44。 | | 9. | Jeste, D. V.、Parmer, B. W.、Harris, M. J.(1999)。Neuroleptic discontinuation in clinical and research settings: scientific issues and ethical dilemmas。Biol Psychiatry，46，1050-1059。 | | 10. | Kapur, S.、Remington, G.(2001)。Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient。Biol Psychiatry，50，873-883。 | | 11. | Tandon, R.、Halbreich, U.(2003)。The second-generation “atypical” antipsychotics: similar improved efficacy but different neuroendocrine side effects。Psychoneuroendocrinology，28(suppl 1)，1-7。 | | 12. | American Diabetes Association、American Psychiatric Association、American Association of Clinical Endocrinologists、North American Association for the Study of Obesity(2004)。Consensus development conference on antipsychotic drugs and obesity and diabetes。Diabetes Care，27，596-601。 | | 13. | American Diabetes Association、American Psychiatric Association、American Association of Clinical Endocrinologists、North American Association for the Study of Obesity(2004)。Consensus development conference on anti-psychotic drugs and obesity and diabetes。J Clin Psychiatry，65，267-272。 | | 14. | 張文和(2001)。建議推行「規範化」藥物治療。台灣精神醫學，15，85-87。 延伸查詢 | | 15. | Ereshefsky, L.(1999)。Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic。J Clin Psychiatry，60(suppl 10)，20-30。 | | 16. | Geddes, J.、Freemantle, N.、Harrison, P.、Bebbington, P.(2000)。Atypical Antipsychotics in the Treatment of Schizophrenia: systematic overview and meta-regression analysis。BMJ，321，1371-1376。 | | 17. | Thomas, C. S.、Levis, S.(1998)。Which atypical antipsychotic?。Br J Psychiatry，172，106-109。 | | 18. | Zarate, C. A. Jr.、Daniel, D. G.、Kinon, B. J.(1995)。Algorithms for the treatment of schizophrenia。Psychopharmacol Bull，31，461-467。 | | 19. | Pearsall, R.、Glick, I. D.、Pickar, D.、Suppes, T.、Tauscher, J.、Jobson, K. O.(1998)。A new algorithm for treating schizophrenia。Psychopharmacol Bull，34，349-353。 | | 20. | Davis, J. M.、Chen, N.、Glich, I.(2003)。A meta-analysis of the efficacy of second-generation antipsychotics。Arch Gen Psychiatry，60，553-564。 | | 21. | Nasrallah, H. A.(2003)。Factors in antipsychotic drug selection: tolerability considerations。CNS Spectr，8(suppl 2)，23-25。 | | 22. | Fontaine, K. R.、Heo, M.、Harrigan, E. P.(2001)。Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate。Psychiatry Res，101，277-288。 | | 23. | Wirshing, D. A.(2004)。Schizophrenia and obesity: impact of antipsychotic medications。J Clin Psychiatry，65(suppl 18)，18-13。 | | 24. | Meyer, J. M.(2001)。Effects of atypical antipsychotics on weight and serum lipid levels。J Clin Psychiatry，62(suppl 27)，27-27。 | | 25. | Jin, H.、Meyer, J. M.、Jeste, D. V.(2002)。Phenomenology and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical anti-psychotics: an analysis of 45 published cases。Ann Clin Psychiatry，14，59-64。 | | 26. | Jin, H.、Meyer, J. M.、Jeste, D. V.(2004)。Atypical antipsychotics and glucose dysregulation: a systematic review。Schizophr Res，71，195-212。 | | 27. | Lane, H. Y.、Chiu, W. C.、Chou, J. C.、Wu, S. T.、Su, M. H.、Chang, W. H.(2000)。Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels。J Clin Psychiatry，61，209-214。 | | 28. | Citrone, L.、Volavka, J.(2004)。The promise of atypical anti-psychotics: fewer side effects mean enhanced compliance and improved functioning。Postgrad Med，116，49-63。 | | 29. | Lin, C. H.、Chen, M. C.、Wang, S. Y.、Lin, C. Y.(2004)。Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics。J Formos Med Assoc，103，437-474。 | | 30. | McCombs, J. S.、Nichol, M. B.、Stimmel, G. L.、Shi, J.、Smith, R. R.(1999)。Use patterns for antipsychotic medications in medicaid patients with schizophrenia。J Clin Psychiatry，60(suppl 19)，5-11。 | | 31. | Lane, H. Y.、Chang, Y. C.、Chiu, C. C.、Lee, S. H.、Lin, C. Y.、Chang, W. H.(2004)。Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants。Psychopharmacology，172，393-399。 | | 32. | Gerlach, J.、Koppelhus, P.、Helweg, E.、Monrad, A.(1974)。Clozapine and haloperidol in a single-blind crossover trial; therapeutic and biochemical aspects in the treatment of schizophrenia。Acta Psychiatr Scand，50，410-424。 | | 33. | Conley, R. R.(1998)。Optimizing treatment with clozapine。J Clin Psychiatry，59(suppl 3)，S44-S48。 | | 34. | 余西金、劉曉鵬(1992)。氯氮平戒斷反應。臨床精神醫學雜誌，2，38-39。 延伸查詢 | | 35. | Llorca, P. M.、Vaiva, G.、Lancon, C.(2001)。Super sensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal。Can J Psychiatry，46，87-88。 | | 36. | Sim, Kang、Su, Alex、Fujii, Senta(2004)。Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia。British Journal of Clinical Pharmacology，58，178-183。 | 圖書| 1. | Barondes, S. H.(2003)。Better Than Prozac: Creating the Next Generation of Psychiatric Drugs。New York：Oxford。 | | 2. | Faweett, J.、Stein, D. J.、Jobson, K. O.(1999)。Textbook of Treatment Algorithms in Psychopharmacology。London：Wiley。 | | 3. | Taylor, D.、Paton, C.、Kerwin, R.(2003)。The Maudsley Prescribing Guidelines。London：Martin Dunitz。 | | 4. | WHO Collaborating Center for Drug Statistic Methodology(2003)。Guidelines for ATC Classification and DDD Assignment。Oslo：WHO Collaborating Center for Drug Statistics Methodology。 | | 5. | Ohlsen, R.、Smith, S.、Taylor, D.、Pilowsky, L.(2003)。The Maudsley Antipsychotic Medication Review Service Guidelines。London：Martin Dunitz。 | | 6. | Taylor, D.、Paton, C.、Kerwin, R.(2005)。The Maudsley Prescribing Guidelines。London：Taylor & Francis。 | | 7. | Bazire, S.(2003)。Psychotropic Drug Dictionary 2003/04。Salisbury：Fivepin。 | | 8. | Carlsson. A.(2004)。Progress in Dopamine Research in Schizophrenia: A Guide for Physicians。Glasgow：Taylor & Francis。 | 圖書論文| 1. | Weinberger, D.(2003)。Dopamine: the prefrontal cortex, and a genetic mechanism of schizophreiiia。Dopamine in the Pathophysiology and Treatment of Schizophrenia。London：Martin Dunitz。 | | 2. | Filippino, S.、Csermansky, J. G.(2004)。Atypical antipsychotic drugs: theories of manchanism of action。Atypical Anti-psychotics From Bench to Bedside。New York：Marcel Dekker。 | | 3. | Chang, W. H.(2002)。Antipsychotics, neurotransmitters, and schizophrenia: a personal Journey from China to Taiwan。From Psychopharmacology to Neuro-Psychophar-macology in the 1980s and the Story of CINP as Told in Autobiography。Budapest：Animula Publishing House。 | | 4. | Stahl, S.(2003)。Key issues and unmet needs in schizophrenia。Dopamine in the Pathophysiology and Treatment of Schizophrenia。London：Martin Dunitz。 | | 5. | Castle, D.、Alderton, D.(2003)。Psychopharmacological management of schizophrenia。Pharmacological and Psychosocial Treatments in Schizophrenia。London：Martin Dunitz。 | | 6. | Loucht, S.、Pitschel-Walz, G.、Kissing, W.、Engell, R. R.(2003)。Dopamine in the Pathophysiology and Treatment of Schizophrenia。Dopamine in the Pathophysiology and Treatment of Schizophrenia。London：Martin Dunitz。 | | 7. | Kapur, S.(2003)。Modulation of dopamine D2 receptors as a basis of antipsychotic effect。Dopamine in the Pathophysiology and Treatment of Schizophrenia。London：Martin Dunitz。 | | 8. | Lecrubier, Y.(2003)。Amisulpride as a model: clinical effects of a pure dopaminergic agent。Dopamine in the Pathophysiology and Treatment of Schizophrenia。London：Martin Dunitz。 | | 9. | Chang, W. H.、Hwu, H. G.(1997)。Plasma HVA and subtyping of schizophrenia。Plasma Homovanillic Acid in Schizophrenia: Implications for Presynaptic Dopamine Dysfunction。Washington DC：American Psychiatric Press。 | |